Novavax reports results from H5N1 vaccine study

Novavax, Inc., recently reported the results of a Phase I/IIa clinical study of the company’s avian H5N1 influenza virus-like particle vaccine candidate.

In an article that appears in the current issue of the Journal of Virology, Novavax listed the safety, immunogenicity, and cross-reactivity results of the 2008 clinical study.

Novavax’s VLP-based vaccine against the highly pathogenic avian H5N1 influenza was shown to be well-tolerated in its subjects, produced no vaccine-related adverse health issues and induced the creation of neutralizing antibodies that were cross reactive to different H5N1 strains.

The testing also resulted in the first report of an unadjuvanted vaccine inducing cross-reactive antibodies against different clades of the H5N1 influenza virus.

"We are excited about these results and insights into the quality of neutralizing and cross-protective antibody responses produced in the study volunteers by our H5N1 VLP vaccine candidate,” Dr. Greg Glenn, the chief medical officer of Novavax, said. “Transmission of the highly pathogenic avian H5N1 flu virus in domestic poultry and humans is continuing in many countries and remains a serious pandemic threat with the potential to evolve into new strains where cross-protection and induction of neutralizing antibodies will be essential.”